马来酸罗格列酮对早期糖尿病肾病患者尿白蛋白排泄的影响被引量：3

Effects of Rosiglitazone on Urinary Albumin Excretion in Patients with Early Diabetic Nephropathy

下载PDF

导出

摘要目的观察马来酸罗格列酮治疗对伴早期肾病2型糖尿病患者尿白蛋白排泄(UAE)的影响。方法将102例早期糖尿病肾病患者随机分为两组:一组给予马来酸罗格列酮4mg/d,另一组给予二甲双胍750mg/d治疗,疗程12周。比较两组治疗前后UAE、糖脂代谢、胰岛素抵抗及血清炎症标志的变化。结果两组空腹血糖、餐后2h血糖、糖化血红蛋白、空腹胰岛素、胰岛素抵抗指数治疗前后比较,差别有统计学意义(P<0.05)。罗格列酮组治疗后UAE、甘油三酯和高敏C反应蛋白下降,高密度脂蛋白胆固醇升高,与治疗前比较,差别有统计学意义(P<0.05)。两组总胆固醇和低密度脂蛋白胆固醇治疗前后比较,差别无统计学意义(P>0.05)。结论罗格列酮能有效降低糖尿病肾病患者的尿蛋白,因此可能对糖尿病血管病变具有临床益处。 Objective To evaluate the effects of rosiglitazone therapy on urinary albumin excretion（UAE）in patients with early diabetic nephropathy （EDN）. Methods 102 EDN patients were randomly allocated into two groups to be treated for 12 weeks with rosiglitazone 4 mg or with mefformin 750 mg daily to compare the UAE, glucose ＆ lipids levels, insulin resistance OR） and serum inflammation markers before and after treatment. Results Levels of FPG, 2 hPG, HbA1c, Fins and HOMA-IR were decreased similarly in two groups after treatment. Rosiglitazone reduced UAE, TG and hsC-RP, increased HDL-C significantly （P〈0.05）, the levels of TC and LDL-C were not significantly changed after treatment （P〉0.05）. Conclusions Rosiglitazone could effectively decrease urinary protein excretion in EDN patients; therefore it might be useful in the treatment of diabetic angiopathy.

作者高璐于德民

机构地区天津医科大学代谢病医院糖尿病足科

出处《中国慢性病预防与控制》 CAS 2007年第2期126-128,共3页 Chinese Journal of Prevention and Control of Chronic Diseases

关键词罗格列酮糖尿病肾病胰岛素抵抗炎症 Rosiglitazone Diabetic nephropathy Insulin resistance Inflammation

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献16

1Sarafidis PA,Lssaridis AN,Nilsson PM,et al.The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension[J].Am J Hypertens,2005,18:227-234.
2Yamashitah,Nagaiy,Takamura T,et al.Thiagolidinedione derivatives ameliorate albuminuria in strettojotocin-induced diabetic spontaneous hytyrtensive rat[J].Metabalism,2002,51:403-408.
3Izzedine H,Launay-Vacher V,Buhaescu I,et al.PPAR-gamma-agonists' renal effects[J].Minerva Urol Nofrol,2005,57:247-260.
4Lam,S,Geest RN.Van der,Verhagen NAM,et al.Secretion of collogen type Ⅳ by human renal fibroblast is increased by high gluase via a TGF-β-independent pathway[J].Nephrol Dial Transplant,2004,19:1694-1701.
5Chang PC,Chen TH,Chang CJ,et al.Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway[J].Kidney Int,2004,65:1664-1675.
6Zheng F,Fornoni A,Elliot SJ,et al.Upregulation of type Ⅰ collagen by TGF-β in mesangial cells is blocked by PPARγactivation[J].Am J Physiol Renal Physiol,2002,282:639-648.
7Zafiriou S,Stanners SR,Saad S,et al.Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts[J].J Am Soc Nephrol,2005,16:638-645.
8Panchapakesan U,Sumual S,Pollock CA,et al.PPARγ agonists exert antifibro-tic effects in renal tubular cells exposed to high glucose[J].Am J Physiol Renal Physiol,2005,289:1153-1158.
9Rosak C.The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents[J].J Diabetes Complications,2002,16:123-132.
10Pistrosch F,Herbrig K,Kindel B,et al.Rosiglitazone improves glomerular hyper filtration,renal endothelial dysfunction,and microalbuminuria of incipient diabetic nephropathy in patients[J].Diabetes,2005,54:2206-2211.